Investment thesis · Live
Washington threatens Brussels with pharma tariffs, and a new plant takes five years: the premium goes to lines already running in the US
Tariffs are pushing drug manufacturing into the US, but new plants won't come online until after 2030, so the pricing power lands with CDMOs that already have approved lines in America.
Published August 16, 2026 · 150-day horizon · regulation
Basket return
+2.7%
equal weight, since publication
The market over the same window
-1.4%
benchmark for this basket
Edge over the market
+4.1%
in percentage points
Causal chain: Section 232 tariffs on pharmaceuticals: manufacture in the US or pay → US pressures Brussels, the 15 percent pharma ceiling hangs by a thread → Drugmakers announce hundreds of billions of US investment → A new plant takes 4 to 6 years, a product transfer 18 to 36 months → The only fast way out: rent existing, approved lines in the US → Almost no free sterile or biologics capacity, reservation fees rising → CDMOs with ready US plants gain pricing power
What this thesis rests on
Each one is a statement that has to be true. When a filing says otherwise, the thesis is in trouble, and this is where we say so.
-
○
US tariffs on imported medicines and APIs remain in force through the 150-day horizon ending 13 January 2027, with no blanket pharmaceutical exemption and no EU-US deal cutting the rate below the 15% ceiling.
regulatory · Unverified
-
○
No plant from the announced US onshoring wave reports a first commercial FDA-approved biologics batch before 2030, and product transfers into existing approved sites still take 18 to 36 months.
operational · Unverified
-
○
US restrictions on Chinese contract manufacturers stay in place through the horizon, so no major Chinese CDMO returns as an approved low-cost route for US-bound sterile fill-finish or biologics output.
competitive · Unverified
-
○
Lonza reports a book-to-bill above 1.0 and a higher CDMO order backlog in its H2 2026 results, and Thermo Fisher reports year-over-year growth in Pharma Services revenue in Q3 and Q4 2026.
financial · Unverified
-
○
Sponsors sign new reservation-fee or take-or-pay capacity agreements at US sites such as Vacaville, Holly Springs, Patheon or Pennsville during the horizon, instead of cutting external manufacturing spend.
competitive · Unverified
The US tariff regime on pharmaceuticals is built around a single condition: manufacture in the US or pay. Drugmakers that have announced plants stateside got tariff relief; everyone else faces the threat of rates running into the tens of percent, and in the extreme case the hundreds. The EU negotiated a ceiling of 15 percent, but that ceiling is part of a broader trade deal that Washington is now publicly pressing Brussels to honor. Pharmaceuticals are the single largest line item in European exports to the States, which makes them the natural hostage in this standoff.
The problem is that the announced investments, which already add up to several hundred billion dollars, solve nothing this decade. A new biologics plant is four to six years from groundbreaking to first commercial batch, and at the end of that road there is still an FDA pre-approval inspection. Even simply moving an existing product into an already operating, approved facility requires a supplement to the registration dossier, a technology transfer, validation runs and comparability studies — typically 18 to 36 months. The tariff, by contrast, bites immediately. Between these two clocks a multi-year gap opens up, and that gap is what this thesis is really about.
Open the interactive thesis
Interactive causal map, the basket charted against its market, and the full timeline.
Open in Invesaro →
This is analysis, not investment advice and not a recommendation to buy or sell anything. We publish it and track it in public, mistakes included. Any decision is yours and yours alone.